Cargando…
Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study
OBJECTIVE: Elevated levels of pro-inflammatory cytokines are observed in severe COVID-19 infections, and cytokine storm is associated with disease severity. Tocilizumab, an interleukin-6 receptor antagonist, is used to treat chimeric antigen receptor T cell-induced cytokine release syndrome and may...
Autores principales: | Huang, Edmund, Isonaka, Sharon, Yang, Haoshu, Salce, Erin, Rosales, Elisa, Jordan, Stanley C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889004/ https://www.ncbi.nlm.nih.gov/pubmed/33609773 http://dx.doi.org/10.1016/j.ijid.2021.02.057 |
Ejemplares similares
-
Tocilizumab in critically ill COVID-19 patients: An observational study
por: Mushtaq, Muhammad Z., et al.
Publicado: (2022) -
553. Critically Ill patients Receiving Tocilizumab Compared With Those Not Receiving Tocilizumab for Treatment of COVID-19
por: Leonard, Michael, et al.
Publicado: (2020) -
Tocilizumab for Covid-19 — The Ongoing Search for Effective Therapies
por: Huang, Edmund, et al.
Publicado: (2020) -
Treatment Outcomes of Tocilizumab in Critically-Ill COVID-19 Patients, Single-Centre Retrospective Study
por: Hafez, Wael, et al.
Publicado: (2022) -
563. Tocilizumab in the Treatment of Critical COVID-19 Pneumonia
por: Fisher, Matthew, et al.
Publicado: (2020)